Anti-IL22 (Fezakinumab)-MC-Vc-PAB-MMAE ADC (ADC-W-1343) 
ADC Target
- Name
- IL22
- Alternative Names
- IL22; interleukin 22; interleukin-22; IL 10 related T cell derived inducible factor; IL 21; IL 22; IL D110; IL TIF; ILTIF; MGC79382; MGC79384; TIFa; TIFIL 23; zcyto18; cytokine Zcyto18; IL-10-related T-cell-derived inducible factor; IL-10-related T-cell-derived-inducible factor; IL-21; IL-22; IL-TIF; IL-D110; TIFIL-23;
- Target Entrez Gene ID
- 50616
- Target UniProt ID
- Q9GZX6
- Overview
- IL22 (Interleukin 22) is a Protein Coding gene. Diseases associated with IL22 include Scleritis and Inflammatory Bowel Disease. Among its related pathways are Akt Signaling and PEDF Induced Signaling. GO annotations related to this gene include cytokine activity and interleukin-22 receptor binding.
ADC Antibody
- Overview
- Human Anti-IL22 IgG1-lambda antibody, Fezakinumab
- Generic name
- Fezakinumab
- Host animal
- Human
ADC Linker
- Name
- MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl)
- Description
- Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
ADC payload drug
- Name
- MMAE
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For lab research use only, not for any in vivo human use.
Subscribe to Our Newsletter and Podcasts for Updates:
